PT  - JOURNAL ARTICLE
AU  - Nogueira, Marta Afonso
AU  - Calcagno, Simone
AU  - Campbell, Niall
AU  - Zaman, Azfar
AU  - Koulaouzidis, Georgios
AU  - Jalil, Anwar
AU  - Alam, Firdous
AU  - Stankovic, Tatjana
AU  - Szabo, Erzsebet
AU  - Szabo, Aniko B.
AU  - Kecskes, Istvan
TI  - Detecting Heart Failure using novel bio-signals and a Knowledge Enhanced Neural Network
AID  - 10.1101/2022.10.26.22281541
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.10.26.22281541
4099  - http://medrxiv.org/content/early/2022/10/27/2022.10.26.22281541.short
4100  - http://medrxiv.org/content/early/2022/10/27/2022.10.26.22281541.full
AB  - Background Clinical decisions about Heart Failure (HF) are frequently based on measurements of left ventricular ejection fraction (LVEF), relying mainly on echocardiography measurements for evaluating structural and functional abnormalities of heart disease. As echocardiography is not available in primary care, this means that HF cannot be detected on initial patient presentation. Instead, physicians in primary care must rely on a clinical diagnosis that can take weeks, even months of costly testing and clinical visits. As a result, the opportunity for early detection of HF is lost.Methods and results The standard 12-Lead ECG provides only limited diagnostic evidence for many common heart problems. ECG findings typically show low sensitivity for structural heart abnormalities and low specificity for function abnormalities, e.g., systolic dysfunction. As a result, structural and functional heart abnormalities are typically diagnosed by echocardiography in secondary care, effectively creating a diagnostic gap between primary and secondary care. This diagnostic gap was successfully reduced by an AI solution, the Cardio-HART™ (CHART), which uses Knowledge-enhanced Neural Networks to process novel bio-signals. Cardio-HART reached higher performance in prediction of HF when compared to the best ECG-based criteria: sensitivity increased from 53.5% to 82.8%, specificity from 85.1% to 86.9%, positive predictive value from 57.1% to 70.0%, the F-score from 56.4% to 72.2%, and area under curve from 0.79 to 0.91. The sensitivity of the HF-indicated findings is doubled by the AI compared to the best rule-based ECG-findings with a similar specificity level: from 38.6% to 71%.Conclusion Using an AI solution to process ECG and novel bio-signals, the CHART algorithms are able to predict structural, functional, and valve abnormalities, effectively reducing this diagnostic gap, thereby allowing for the early detection of most common heart diseases and HF in primary care.Competing Interest StatementIstvan Kecskes disclosure: Research director at UVA research Corp., no other industry connections. Other authors have no financial or personal relationships with other people or organizations that could inappropriately influence their work.Funding StatementThe collection of the data used in this paper was previously collected in clinical investigations funded in part by UVA Research Corp., no other outside funding was involved.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Senta Hospital and Regional Hospital Dr Radivoj Simonovic Sombor gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on reasonable request. The clinical data are for legitimate purposes on request. The Official Study Report can be obtained on request: info{at}cardiophoenix.com